Citation Impact 2023
Journal Impact Factor: 6.1
5-year Journal Impact Factor: 7.1
Source Normalized Impact per Paper (SNIP): 1.865
SCImago Journal Rank (SJR): 2.578
Speed 2023
Submission to first editorial decision (median days): 14
Submission to acceptance (median days): 129
Usage 2023
Downloads: 2,432,781
Altmetric mentions: 1,561
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had...